Lanvin Group Holdings Limited (LANV)
Market Cap | 798.92M |
Revenue (ttm) | 510.52M |
Net Income (ttm) | -134.97M |
Shares Out | 130.97M |
EPS (ttm) | -1.36 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 86,833 |
Open | 5.90 |
Previous Close | 6.06 |
Day's Range | 5.86 - 6.48 |
52-Week Range | 4.19 - 22.81 |
Beta | 0.06 |
Analysts | Sell |
Price Target | 6.63 (+8.69%) |
Earnings Date | Mar 30, 2023 |
About LANV
Lanvin Group Holdings Limited operates in the fashion sector worldwide. It offers various fashion products under the Lanvin, Sergio Rossi, Wolford, St. John Knits, and Caruso brands. The company was founded in 1889 and is based in Shanghai, China. Lanvin Group Holdings Limited operates as a subsidiary of Fosun International Limited. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LANV stock is "Sell." The 12-month stock price forecast is $6.63, which is an increase of 8.69% from the latest price.
News

Lanvin's IPO Strengthens The Fall Winter 2023 Collection
Creative Director Bruno Sialelli's latest offering for the 134-year-old houses singled wearable merchandise with a high interest quotient.

Lanvin Group Achieves Record Sales in 2022
P reliminary Revenues Up 38% Year-on-Year Revenues of €425 million for FY2022, a 38% increase on FY 2021, exceeding previous guidance (1) All portfolio brands delivered growth, with flagship brand Lan...

Lanvin Group to Report 2022 Full-Year Preliminary Revenues on February 17, 2023
NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group, today opened registration for its first revenue results conference call since its public...

Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep exper...

Lanvin Group Plans to Announce 2022 Full-Year Preliminary Revenue Results on February 17, 2023; Announces Management Change
NEW YORK , Jan. 31, 2023 /PRNewswire/ -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group, today announced that it will report its unaudited full-year 2022 preliminary revenue res...

Lanvin Group Appoints Veteran Entertainment Executive, Ceci Kurzman as a New Independent Director; and Announces Changes in Composition of Board Committees
NEW YORK, Jan. 6, 2023 /PRNewswire/ -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group, today announced the appointment of Ms. Ceci Kurzman as a new independent director to its B...

Lanvin Group Debuts on NYSE under Ticker "LANV"
NEW YORK , Dec. 15, 2022 /PRNewswire/ -- Lanvin Group (the "Group"), a global luxury fashion group, and Primavera Capital Acquisition Corporation (NYSE: PV) ("PCAC"), today announced the completion o...

New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep exper...

Lanvin Group and Primavera Capital Acquisition Corporation Announce Updates in Relation to Business Combination
South Korea's Handsome Corporation will join Lanvin Group's roster of strategic investors Business combination agreement amended to remove closing condition in relation to minimum amount of cash Prima...

Lanvin Group and Primavera Capital Acquisition Corp. Announces Effectiveness of Registration Statement and Extraordinary General Meeting Date for Proposed Business Combination
SHANGHAI , Nov. 4, 2022 /PRNewswire/ -- November 4, 2022 – Lanvin Group (the "Group"), a global luxury fashion group, today announced that, the U.S. Securities and Exchange Commission ("SEC") has decl...